It Seems Ultragenyx Pharmaceutical Inc Will Go Up. Had Bullish Options Activity

 It Seems Ultragenyx Pharmaceutical Inc Will Go Up. Had Bullish Options Activity

In today’s session Ultragenyx Pharmaceutical Inc (RARE) registered an unusually high (151) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious RARE increase. With 151 contracts traded and 2374 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: RARE161021C00075000 closed last at: $1.5 or 36.2% down. About 88,013 shares traded hands. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has risen 10.30% since March 11, 2016 and is uptrending. It has outperformed by 4.84% the S&P500.

Analysts await Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings on November, 14. They expect $-1.58 EPS, down 53.40% or $0.55 from last year’s $-1.03 per share. After $-1.46 actual EPS reported by Ultragenyx Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 8.22% negative EPS growth.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Ratings Coverage

Out of 12 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 12 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $126 is the highest target while $67 is the lowest. The $105.77 average target is 63.81% above today’s ($64.57) stock price. Ultragenyx Pharmaceutical Inc has been the topic of 20 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Friday, February 19 by Leerink Swann. Morgan Stanley downgraded it to “Equal Weight” rating and $126 target price in Monday, July 27 report. Jefferies initiated it with “Buy” rating and $108 target price in Friday, October 23 report. SunTrust maintained Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on Monday, July 13 with “Buy” rating. The firm has “Buy” rating given on Tuesday, December 22 by Canaccord Genuity. The firm has “Sell” rating given on Thursday, September 3 by Citigroup. The firm earned “Buy” rating on Tuesday, June 28 by Bank of America. The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has “Buy” rating given on Tuesday, December 1 by Stifel Nicolaus. On Tuesday, August 18 the stock rating was downgraded by Zacks to “Buy”. The firm has “Outperform” rating by Raymond James given on Tuesday, September 1.

According to Zacks Investment Research, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.”

Insitutional Activity: The institutional sentiment decreased to 0.97 in 2016 Q2. Its down 0.12, from 1.09 in 2016Q1. The ratio dived, as 19 funds sold all Ultragenyx Pharmaceutical Inc shares owned while 55 reduced positions. 19 funds bought stakes while 53 increased positions. They now own 36.54 million shares or 1.13% less from 36.95 million shares in 2016Q1.
Jennison Ltd Liability Corp has 498,041 shares for 0.03% of their US portfolio. Schwab Charles Investment Management Inc last reported 170,806 shares in the company. Fort Point Prtn Limited Liability Company accumulated 8,000 shares or 0.19% of the stock. Bluemountain Cap Ltd Liability Corporation holds 6,770 shares or 0.01% of its portfolio. Swiss Commercial Bank has invested 0% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Td Asset Mgmt Inc has invested 0% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Proshare Ltd Liability has invested 0.02% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Credit Suisse Ag, a Switzerland-based fund reported 141,187 shares. State Board Of Administration Of Florida Retirement Systems holds 24,342 shares or 0% of its portfolio. Profund Advsrs Limited Liability Corporation holds 20,106 shares or 0.05% of its portfolio. Moreover, Rhenman Partners Asset Management Ab has 0.09% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 10,000 shares. The Connecticut-based Aqr Capital Mngmt Limited Liability has invested 0% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Strs Ohio last reported 0% of its portfolio in the stock. Fred Alger Mngmt last reported 0.02% of its portfolio in the stock. The New Jersey-based Princeton Alpha Mgmt L P has invested 0.04% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $2.57 billion. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. It currently has negative earnings. The Firm is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

RARE Company Profile

Ultragenyx Pharmaceutical Inc., incorporated on June 13, 2011, is a clinical-stage biopharmaceutical company. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Firm is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies.

More news for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) were recently published by: Prnewswire.com, which released: “Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research …” on October 29, 2015. Investorplace.com‘s article titled: “3 Stocks to Watch on Thursday: Monsanto Company (MON), Ultragenyx …” and published on July 14, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment